COMPARISON OF PSORALEN ULTRAVIOLET A (PUVA) PHOTOCHEMOTHERAPY PLUS TOPICAL CORTICOSTEROIDS WITH PUVA PLUS BLAND EMOLLIENTS IN THE TREATMENT OF PSORIASIS

Authors

  • Raheel Tahir
  • Ghulam Mujtaba

Abstract

Background: Psoralen Ultraviolet A (PUVA) therapy is a well-established treatment of psoriasis. The objective of the study was to compare the clinical improvement in psoriasis with PUVA photochemotherapy + topical corticosteroids and PUVA + bland emollients. Methods: Forty patients with chronic plaque type of psoriasis were divided into two equal groups each having 20 patients. PUVA therapy was given thrice weekly. In addition, patients of group-A were allowed to apply topical betamethasone 17-valerate 0.1% diluted 1 into 2 parts with plain vaseline twice daily. Patients of group-B were allowed to apply only plain vaseline over lesions twice daily. Clinical improvement in lesions was observed by decrease in the severity of erythema, scaling and plaque elevation. Results: Clearance of psoriasis was achieved in 95% of the patients treated with PUVA plus topical corticosteroids while clearance was achieved in 80% of patients treated with PUVA plus bland emollients (P=0.0758). Median numbers of exposures for group-A were 16 & for group-B were 17.5 (p= 0.1029). Similarly, median cumulative dose in group-A was 64.5 J/cm2 & in group-B was 70.7 J/cm2 (p= 0.372). Conclusion: There is no significant difference in clinical improvement in psoriasis treated either by PUVA plus topical steroids or PUVA plus bland emollients.

Key Words: Psoriasis, PUVA therapy, Betamethasone 17-valerate, Emollients

 

References

Hirji S, Kanji A. Use of cyclosporine-A in the treatment of acute generalized pustular psoriasis. J Pakistan Assoc Derma 2000; 11: 48-53.

Christophers E, Mrowietz U. Psoriasis. In: Fitzpatrick TB, Eisen A, Wolff K, Freedberg IM, Austen KF. Dermatology in general medicine. New York: Mcgraw Hill, 1999: 495-521.

Lebwohh M, Sheren D, Washenik K, Krueger GG, Menter A, Koo J et al. A randomized, double blind, placebo controlled study of clobetasol propionate 0.05% foam in the treatment of non-scalp psoriasis. Int J Dermatol 2002; 41: 269-74.

Pierard GE, Pierard-Franchimont C, Mosbah TB, Estrada JA. Adverse effects of topical corticosteroids. Acta Derm Venereol (Stockh) 1989; 69 (Suppl 151): 26-30.

Abma EM, Blanken R, De Heide LJ. Cushing's syndrome caused by topical steroid therapy for psoriasis. Neth J Med 2002; 60: 148-50.

Du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol 1975; 111: 581-3.

Liem WH. McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995; 55: 306-10.

Mujtaba G, Khalid M. PUVA therapy for psoriasis. Ann King Edward Med Coll 1999; 5: 78-9.

Alge C, Baxter RM, Doyle ME, Moor AC, Brissette JL, Ortel B. PUVA down regulates whn expression in primary mouse keratinocytes. J Photochem Photobiol 2001; 64: 75-81.

Khurshid K, Haroon TS. Photochemotherapy in dermatology. J Coll Physicians Surg Pak 2000; 10:153-4.

Stern RS. The risk of melanoma in association with long term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61.

Feldmann SR, Garton R, Averett W, Vallee J, Balkrishnan R. Strategy of manage the treatment of severe psoriasis: considerations of efficacy, safety and cost. Expert Opin Pharmacother 2003;4:1525-33.

Tzaneva S, Henigsmann H, Tanew A, Seeber A. A comparison of psoralen plus ultraviolet A (PUVA) monotherapy, tacalcitol plus PUVA and tazarotene plus PUVA in patients with chronic plaque type psoriasis. Br J Dermatol 2002; 147(4): 748-53.

Boyuat A, Erdi H, Birol A, Guvgey E. Interaction of commonly used emollients with photochemotherapy. Photodermatol Photoimmunol Photomed 2000; 16: 156-60.

Epstein JH, Farber EM, Nall L. Current status of oral PUVA therapy for psoriasis. J Am Acad Dermatol 1979;1:106-17.

Anderson TF, Waldinger TP, Voorhees JJ. UV-B phototherapy: an overview. Arch Dermatol 1984;120:1502-7.

Meola T, Soter NA, Lim HW. Are topical corticosteroids useful adjunctive therapy for the treatment of psoriasis with UV radiation? Arch Dermatol 1991;127:1708-13.

Dower JS. Are topical corticosteroids useful in phototherapy for psoriasis? J Am Acad Dermatol 1989; 20: 748-51.

Levine MJ, Parrish JA. The effect of topical fluocinonide ointment on phototherapy of psoriasis. J Invest Dermatol 1989; 157: 78-82.

Kostovic K, Situm M, Nola I. Phototherapy (UVB) and photochemotherapy (PUVA) for psoriasis. Acta Clin Croat 2002; 41: 103-12.

Downloads

How to Cite

Tahir, R., & Mujtaba, G. (2005). COMPARISON OF PSORALEN ULTRAVIOLET A (PUVA) PHOTOCHEMOTHERAPY PLUS TOPICAL CORTICOSTEROIDS WITH PUVA PLUS BLAND EMOLLIENTS IN THE TREATMENT OF PSORIASIS. Journal of Ayub Medical College Abbottabad, 17(1). Retrieved from https://jamc.ayubmed.edu.pk/index.php/jamc/article/view/4114

Issue

Vol. 17 No. 1 (2005): JOURNAL OF AYUB MEDICAL COLLEGE, ABBOTTABAD

Section

ORIGINAL ARTICLE

License

Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License  CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.

USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.

AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.